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later by cervical adenopathy, leukocytosis (17,700 
white cells per cubic millimeter, with 5% ana-
plastic large-cell lymphoma cells), and respira-
tory distress due to interstitial lung involvement. 
Quantitative PCR testing performed on day 20 
showed 117 copies of NPM-ALK per 10,000 cop-
ies of ABL and confirmed the relapse (Fig. 1B). 
Treatment with ceritinib (at a dose of 450 mg per 
square meter) was started on day 23 and induced 
a rapid clinical improvement, radiologic complete 
remission, and negative findings on quantitative 
PCR testing 113 days after discontinuation of 
crizotinib. Both patients remained in complete 
remission and continued to receive treatment.
In these two patients, residual neoplastic cells 
persisted for up to 3 years during crizotinib 
treatment. Quiescent stem cells have been shown 
to cause persistent PCR positivity and residual 
disease in chronic myeloid leukemia treated with 
imatinib, although they do not appear to inter-
fere with the excellent prognosis of patients with 
the disease.5 These findings suggest that caution 
must be exercised when interrupting treatment 
in patients with ALK-positive lymphomas, since 
anaplastic large-cell lymphoma may recur rapidly. 
PCR testing to measure levels of NPM-ALK has 
limited ability to detect residual disease. The 
indicator of relapse may be the patient’s clinical 
symptoms rather than the results of quantita-
tive PCR testing or combined positron-emission 
tomography and CT.
Patients who have received crizotinib for early 
relapses after allogeneic bone marrow transplan-
tation may be an exception. In these patients, 
temporary crizotinib treatment has resulted in 
durable remissions,2 possibly because of an anti-
ALK immune response mounted by the graft.
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Ebola Virus Disease among Male and Female Persons  
in West Africa
To the Editor: From December 2013 to August 
11, 2015, a total of 20,035 confirmed and prob-
able cases of Ebola virus disease (EVD) were re-
ported in Guinea, Liberia, and Sierra Leone. There 
have been concerns that the different cultural 
roles or physiology of male and female persons 
may have resulted in the sexes being differently 
affected during this outbreak.1,2
Data on confirmed, probable, and suspected 
EVD cases (according to World Health Organiza-
tion [WHO] case definitions3) were collected 
with the use of a standard case-investigation 
form4 in Guinea, Liberia, Nigeria, and Sierra 
Leone. This form is completed when a case is 
detected and the patient is admitted to a health 
care facility as part of the public health response 
to the outbreak. We used data on confirmed and 
probable EVD cases in Guinea, Liberia, and Sierra 
Leone to compare sex-specific epidemiologic pat-
terns. Some records were not complete, but ow-
ing to the size and overall detail of the data, we 
assessed whether there were any differences ac-
cording to sex.
Within each district, we compared the pro-
portion of the population who were male with 
the proportion of patients with EVD who were 
male. For each country, we also tested for sex-
related differences in incubation period, time 
from symptom onset to hospitalization, dura-
tion of hospitalization (separately for fatalities 
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and survivors), case fatality rate, clinical signs 
and symptoms, and reported exposures to sick 
persons.4,5 We estimated the case fatality rate 
using recorded final status, excluding data from 
patients with a date of report on or after the date 
that the final status was entered into the data-
base, as in our previous reports in the Journal.4,5
Overall, 48.8% of the 20,035 confirmed and 
probable EVD cases were in male persons. The 
proportion of patients with EVD who were male 
(47.3% in Guinea, 50.2% in Liberia, and 48.8% 
in Sierra Leone) did not differ significantly from 
the proportion of the population who were male 
in any country (48.5% in Guinea, 50.0% in Liberia, 
and 48.2% in Sierra Leone) (Table S1 in the Sup-
plementary Appendix, available with the full text 
of this letter at NEJM.org). However, the propor-
tions were significantly different in Gueckedou 
district, Guinea, which had an unusually low 
proportion of patients who were male (36.6%, 
P<0.001).
The average interval from symptom onset to 
hospitalization was approximately 0.5 days short-
er among female patients than among male pa-
tients in all countries (P<0.05 for all compari-
sons) (Table 1), driven by cases at the peak of the 
epidemic (Table S6 in the Supplementary Appen-
dix). Female patients were significantly less likely 
to die than were male patients (case fatality rate, 
63.0% vs. 67.1%; odds ratio, 0.83; 95% confi-
dence interval, 0.77 to 0.91) (Table S8 and Sec-
tion 3.3 in the Supplementary Appendix). This 
survival difference remained significant when 
we adjusted for age group (in 5-year intervals), 
clinical signs and symptoms, and interval from 
symptom onset to hospitalization (Section 3.4 in 
the Supplementary Appendix). In addition, al-
though a higher proportion of female patients 
than male patients reported an exposure to a 
sick person, the number of exposures reported 
by female and male patients did not differ sig-
nificantly (Section 3.5 in the Supplementary Ap-
pendix).
Results did not change significantly when we 
restricted the analysis to confirmed cases (80.8% 
of the 20,035 cases). Further details on all results 
are provided in the Supplementary Appendix.
We found that male and female persons have 
similar risks, on average, of EVD. However, there 
were significant differences — in particular, the 
higher survival rate among female patients. Male 
patients spent 12.5% longer (approximately 12 
hours) on average in the community while 
symptomatic, which could be particularly im-
portant if infectiousness increases after onset, 
making the risk of transmission in that last half-
day higher than average. This suggests that, for 
control purposes, public health measures to re-
duce community-based transmission might ben-
efit from awareness of sex-specific differences.
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